Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01834937 · ClinicalTrials.gov registry record
ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
A clinical trial, sponsored by InSightec.
- Terminated
- Registry status
- 17
- Enrollment target
NCT01834937 is a clinical trial that was terminated before completion, run by InSightec. The registered enrollment target is 17 participants.
The verdict
NCT01834937 was terminated before completion, sponsored by InSightec.
- TERMINATED
- Registry status
- 17 participants
- Enrollment target
Study Summary
The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.
Interventions
- DEVICE ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-06 |
| Est. Completion | 2017-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01834937
The ClinicalTrials.gov registry entry for NCT01834937 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery) is the first listed.
NCT01834937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01834937 about?
NCT01834937 is a clinical study titled "ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain". The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in pa...
What is the current status of trial NCT01834937?
This trial is currently terminated. The enrollment target is 17 participants. The study started on 2013-06. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01834937?
The interventions under investigation include: ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery) (DEVICE).
Who is sponsoring clinical trial NCT01834937?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.